Oregon Health & Science University researchers say they have created a new “one-two punch” to be used to combat hard-to-manage cancerous tumors.

A commentary piece in the Oregon Capital Chronicle on the 340B drug discount program mentions OHSU and other hospitals.

A story in Psy Post highlights how brain connectivity patterns differ in children and adolescents diagnosed with generalized anxiety disorder. Study author Sam A. Sievertsen, a Ph.D. student in clinical psychology, says, “Generalized anxiety disorder emerges in childhood or adolescence for some individuals, but a lot of what we know about brain connectivity comes from adult studies.”

Ahmad Masri, M.D., is among leading experts interviewed by HCP Live about the latest treatment advancements for amyloidosis.

In a KGW-TV story about a proposed state law allowing foster youths to be placed out of state for housing and treatment, Ajit Jetmalani, M.D., says, “There are many, many reports of potential abuse or neglect that are not founded. Each one of these reports causes the [medical provider] to be anxious, fearful for their jobs and their livelihoods.”

An oft-ignored type of brain cell plays a dynamic and surprisingly complex role in our ability to process information, according to an OHSU study published in the journal Science. Marc Freeman, Ph.D., says, “We hope this begins to fundamentally change how the field thinks about astrocytes and their role in mediating neurophysiology and behavior. Over the long run, it should change how people think about developing therapies for regulation of attention, anxiety and mood.”

P. Barton Duell, M.D., is the featured guest on a Rarecast podcast, speaking about the role OHSU played in developing a diagnostic and advancing a treatment for CTX, or Cerebrotendinous Xanthomatosis, a rare autosomal recessive genetic disorder, and the critical interplay between academic health centers, patient advocates and drug developers to address the needs of people with rare diseases.

A new nanoparticle developed by OHSU researchers that makes cancer treatment safer and more effective. Michael Henderson, B.A., says the research “lays the foundation for a new kind of nanoparticle-based therapy that could improve how we approach hard-to-treat tumors.”

A groundbreaking advancement in cancer treatment has emerged from researchers at Oregon Health & Science University (OHSU), where a novel nanoparticle technology is poised to revolutionize the way high-intensity focused ultrasound (HIFU) is used against solid tumors.

A new nanoparticle developed by OHSU researchers that makes cancer treatment safer and more effective. Michael Henderson, B.A., says the research “lays the foundation for a new kind of nanoparticle-based therapy that could improve how we approach hard-to-treat tumors.”